← All trials
NCT05242432
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2022
- Primary completion
- Mar 15, 2023
- Completion date
- Mar 15, 2023
- First posted
- Feb 16, 2022
- Last posted
- Oct 26, 2022
- Enrollment
- 2180
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Janssen Pharmaceutica NVLead sponsor
- Janssen Pharmaceutica NVStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.